We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Stool Biomarker Screening Tests Detect Colorectal Cancer and Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 12 Jul 2021
Print article
Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease (Photo courtesy of Wikimedia Commons)
Two recent papers described the use of novel stool protein biomarkers in screening tests to diagnose colorectal cancer (CRC) and inflammatory bowel disease (IBD).

The attributable risk of developing IBD (ulcerative colitis and Crohn's disease) is about 0.5% in the general population, with IBD affecting about 1.6 million Americans, including as many as 80,000 children. With over 20% of cases being diagnosed before the age of 17, IBD is one of the most common gastrointestinal chronic diseases affecting children and adolescents. Globally more than one million people get colorectal cancer every year resulting in more than 715,000 deaths. CRC has been the second most common cause of cancer in women (9.2% of diagnoses) and the third most common in men (10.0%), and has been the fourth most common cause of cancer death after lung, stomach, and liver cancer. People with inflammatory bowel disease (ulcerative colitis and Crohn's disease) are at increased risk of developing colon cancer.

Investigators at the University of Houston (TX, USA) conducted studies to identify and validate stool protein biomarkers for diagnosis of CRC and IBD. In one study, published in the June 12, 2021, online edition of the Journal of Gastroenterology, a novel aptamer-based screen of 1317 proteins was used to uncover elevated proteins in the stool of patients with CRC, as compared to healthy controls (HCs). A total of 92 proteins were significantly elevated in CRC samples as compared to HCs. Among Caucasians, the five most discriminatory proteins among the 16 selected proteins, ordered by their ability to distinguish CRC from adenoma and healthy controls, were MMP9, haptoglobin, myeloperoxidase, fibrinogen, and adiponectin. Excepting myeloperoxidase, the markers were significantly associated with depth of tumor invasion.

In another study, which was published in the June 28, 2021, online edition of the journal Nature Communications, an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Results of the screen revealed that of the 20 proteins subsequently validated by ELISA, stool ferritin, fibrinogen, haptoglobin, hemoglobin, lipocalin-2, MMP-12, MMP-9, myeloperoxidase, PGRP-S, properdin, resistin, serpin A4, and TIMP-1 were significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) as compared to controls.

Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues, and organisms. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.

"The unique aspect of both research reports is that we are looking at stool samples comprehensively, and not just at one or two favorite molecules," said senior author Dr. Chandra Mohan, professor of biomedical engineering in the University of Houston. "We are casting a wide net, and this has never been done before. Using the new biomarkers, we can predict if the disease will become worse or if the intestines will become more inflamed. Stool proteins assayed at baseline can predict how the disease might progress in the weeks and months ahead. By the time you see blood, it might be too late, and there are other proteins that appear in the stool if someone has colon cancer, and they may appear much earlier than when the blood appears. We demonstrate the utility of comprehensive aptamer-based proteomic screens in identifying novel disease biomarkers for IBD that outperform the current gold standard, fecal calprotectin."

Related Links:
University of Houston

Gold Supplier
Microplate-Strip Washer
Wellwash Versa
Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Isothermal Microfluidic Chip Analyzer
CapitalBio RTisochip
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg

Print article


Copyright © 2000-2022 Globetech Media. All rights reserved.